FDA Grants Fast Track Designation for Lomecel-B in Alzheimer's Treatment
Wednesday, 17 July 2024, 12:36
FDA Fast Track Designation
Longeveron Inc. has received Fast Track designation from the FDA for their Alzheimer's treatment, Lomecel-B.
Accelerated Development Process
This designation accelerates the drug development and market approval process, aiming for faster availability.
Stock Price Surge
Investors reacted positively to the news, resulting in a significant increase in Longeveron's stock value.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.